JPS6270318A - Hemostatic and wound-protecting agent - Google Patents
Hemostatic and wound-protecting agentInfo
- Publication number
- JPS6270318A JPS6270318A JP21009485A JP21009485A JPS6270318A JP S6270318 A JPS6270318 A JP S6270318A JP 21009485 A JP21009485 A JP 21009485A JP 21009485 A JP21009485 A JP 21009485A JP S6270318 A JPS6270318 A JP S6270318A
- Authority
- JP
- Japan
- Prior art keywords
- wound
- agent
- powder
- hemostatic
- average particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 7
- 239000003223 protective agent Substances 0.000 title abstract 2
- 239000000843 powder Substances 0.000 claims abstract description 23
- 239000002245 particle Substances 0.000 claims abstract description 8
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 7
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 7
- 239000011814 protection agent Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 abstract description 9
- 230000023597 hemostasis Effects 0.000 abstract description 7
- XQVWYOYUZDUNRW-UHFFFAOYSA-N N-Phenyl-1-naphthylamine Chemical compound C=1C=CC2=CC=CC=C2C=1NC1=CC=CC=C1 XQVWYOYUZDUNRW-UHFFFAOYSA-N 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000006467 substitution reaction Methods 0.000 abstract description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 4
- 239000003589 local anesthetic agent Substances 0.000 abstract description 4
- 229910052708 sodium Inorganic materials 0.000 abstract description 4
- 239000011734 sodium Substances 0.000 abstract description 4
- 108010010803 Gelatin Proteins 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 229920000159 gelatin Polymers 0.000 abstract description 3
- 239000008273 gelatin Substances 0.000 abstract description 3
- 235000019322 gelatine Nutrition 0.000 abstract description 3
- 235000011852 gelatine desserts Nutrition 0.000 abstract description 3
- 102000008186 Collagen Human genes 0.000 abstract description 2
- 108010035532 Collagen Proteins 0.000 abstract description 2
- 229920001436 collagen Polymers 0.000 abstract description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 abstract description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000004098 Tetracycline Substances 0.000 abstract 1
- 229940120889 dipyrone Drugs 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 abstract 1
- 229920005615 natural polymer Polymers 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002633 protecting effect Effects 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 229960002180 tetracycline Drugs 0.000 abstract 1
- 229930101283 tetracycline Natural products 0.000 abstract 1
- 235000019364 tetracycline Nutrition 0.000 abstract 1
- 150000003522 tetracyclines Chemical class 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 206010052428 Wound Diseases 0.000 description 16
- -1 temerosal Chemical compound 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000840 dequalinium Drugs 0.000 description 1
- PCSWXVJAIHCTMO-UHFFFAOYSA-P dequalinium Chemical compound C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 PCSWXVJAIHCTMO-UHFFFAOYSA-P 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229910000464 lead oxide Inorganic materials 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
- YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 1
- 229960001544 sulfathiazole Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は止血及び創傷保護剤に関する。[Detailed description of the invention] [Industrial application field] The present invention relates to hemostatic and wound protection agents.
従来、止血及び創傷保護を目的とした製剤としては例え
ば、馬れいしよ澱粉、乳糖、硫酸フラジオマイシンから
なる散剤が知られている。Conventionally, as a preparation for the purpose of hemostasis and wound protection, for example, a powder consisting of horse starch, lactose, and fradiomycin sulfate is known.
しかし、これらの製剤は止血性が十分でなかったり、又
、創傷保護が十分でないという欠点がある。However, these preparations have drawbacks such as insufficient hemostatic properties and insufficient wound protection.
そこで本発明者らは種々検討した結果、ポリアクリル酸
ナトリウム（以下［Ｐ Ａ Ｎ Ａｊという）粉末がす
ぐれた止血作用及び創傷保護作用を発揮することを見い
出した。As a result of various studies, the present inventors have discovered that sodium polyacrylate (hereinafter referred to as PAN Aj) powder exhibits excellent hemostasis and wound protection effects.
本発明は上記知見に基づき完成されたものである。The present invention has been completed based on the above findings.
本発明で用いられるＰＡＮＡは部分的に架橋されていて
もよく、又、その平均分子量は５０万以上、より好まし
くは１５０万以上のものである。PANA used in the present invention may be partially crosslinked, and has an average molecular weight of 500,000 or more, more preferably 1,500,000 or more.
また、ナトリウムイオンの置換度は２０〜１００チ、よ
り好ましくは４０〜１００チである。Further, the degree of substitution of sodium ions is 20 to 100 degrees, more preferably 40 to 100 degrees.
ＰＡＮＡ粉末の平均粒径は１４０μｍ以下、好ましくは
１００μｍ以下、さらに好ましくは３０μｍ〜３μｍ程
度である（顕微鏡法）。The average particle size of the PANA powder is 140 μm or less, preferably 100 μm or less, and more preferably about 30 μm to 3 μm (microscopic method).
本発明の止血及び創傷保護剤には創傷の治癒の促進に有
用な薬剤が配合されていてもよい。The hemostasis and wound protection agent of the present invention may contain a drug useful for promoting wound healing.
薬剤としては、例えばテトラザイクリン、ベンジルペニ
シリン、アンピシリン、アモキシシリン、セファロチン
ナトリウム、エリスロマイシン、塩酸テトラサイクリン
、硫酸フラジオマイゾン、硫酸ゲンタマイシン、スルフ
ァチアゾール、クロルヘキシジン、テメロサール、ヨー
ドホルム、ホウ酸、パラホルムアルデヒド、塩化デカリ
ニウム、ポビドンヨードなどの抗菌性薬剤、スルビリン
、アンチピリン、アスピリン、フェニルブタシン。Examples of drugs include tetrazycline, benzylpenicillin, ampicillin, amoxicillin, cephalothin sodium, erythromycin, tetracycline hydrochloride, fradiomizone sulfate, gentamicin sulfate, sulfathiazole, chlorhexidine, temerosal, iodoform, boric acid, paraformaldehyde, chloride. Antibacterial agents such as dequalinium, povidone-iodine, survirin, antipyrine, aspirin, phenylbutacin.
メフェナム酸、ジクロフェナックナトリウム、ケトプロ
フェン、イブプロフェン、デキザメサゾン、トリアムシ
ノロンアセトニド、プロスタグランジンなどの抗炎症剤
、アミノ安息香酸エチル、塩酸テトラカイン、塩酸リド
カインなどの局所麻酔剤などがあげられる。その配合量
は製剤全量に対し２〜３０％１局所麻酔剤の場合０．０
１〜４％、好ましくは０．１〜２チ程度である。Examples include anti-inflammatory agents such as mefenamic acid, diclofenac sodium, ketoprofen, ibuprofen, dexamethasone, triamcinolone acetonide, and prostaglandins, and local anesthetics such as ethyl aminobenzoate, tetracaine hydrochloride, and lidocaine hydrochloride. The amount added is 2 to 30% of the total amount of the preparation.1 In the case of local anesthetics, it is 0.0%.
It is about 1 to 4%, preferably about 0.1 to 2%.
本発明の製剤は、粉末剤、軟膏として、又、それらをシ
ートに塗布したシート状の製剤として創傷面に直接膜力
すれるが粉末剤が好寸しい。The preparation of the present invention can be applied directly to the wound surface in the form of a powder, an ointment, or a sheet-like preparation prepared by coating them on a sheet, but a powder is preferable.
粉末剤の場合、ＰＡＮＡ粉末をその才ま粉末剤としても
よいが通常はＰＡＮＡ粉末を、所望により薬剤とともに
外用の粉末剤の基剤、例えば、澱粉。In the case of a powder, PANA powder may be used as a powder, but usually PANA powder is used together with a drug, if desired, as a base for a powder for external use, such as starch.
乳糖、タルク、カオリン、シリカ、酸化唾鉛、アビセル
、エロージル、スメクタイト及び蜜ロウ等のロウ類の粉
末に添加し、均一に混合し７て、成型粉砕することなく
そのま１粉末剤とする。It is added to the powder of waxes such as lactose, talc, kaolin, silica, salivary lead oxide, Avicel, Erosil, smectite, and beeswax, mixed uniformly, and made into a single powder without being molded and crushed.
基剤の使用量は製剤全量に対して８ｏ％以下より好まし
くは５０〜５％である。The amount of the base used is 80% or less, preferably 50 to 5%, based on the total amount of the preparation.
軟膏は常法により１例えばＰ Ａ、 Ｎ Ａ粉末を所望
により薬剤とともに軟膏基剤に添加し、均一に混合する
ことにより製造される。ここで使用される軟膏基剤とし
ては１例えば各種の植物油、脂肪酸トリグリセリド、プ
ラスチベース、ワセリンなどの油性基剤が好ましい。こ
の製剤中のＰＡＮＡＯ量は製剤全量に対し５−８０％、
より好ましくは１０〜６５％である。Ointments are manufactured by adding powders such as PA, NA powder, if desired, along with drugs to an ointment base and mixing uniformly in a conventional manner. The ointment base used here is preferably an oily base such as various vegetable oils, fatty acid triglycerides, Plastibase, and petrolatum. The amount of PANAO in this preparation is 5-80% of the total amount of the preparation,
More preferably it is 10 to 65%.
又１本発明の止血及び創傷保護剤には他の添加剤が添加
されていてもよい。添加剤としては例えばコラーゲン、
ゼラチンなどの天然の水溶性高分子があげられる。Further, other additives may be added to the hemostasis and wound protection agent of the present invention. Examples of additives include collagen,
Examples include natural water-soluble polymers such as gelatin.
これらの添加量は、ＰＡＮＡに対して３０％以下、より
好ましくは２０％以下である。The amount of these added is 30% or less, more preferably 20% or less based on PANA.
出血を伴う切り傷や擦過傷を手及び足に受傷したボラン
ティア１０名に対し１本発明品又は対照品を適用し、止
血状態と傷の固定修復状態を観察した。One of the products of the present invention or a control product was applied to 10 volunteers who had sustained bleeding cuts or abrasions on their hands and feet, and the state of hemostasis and the state of fixation and repair of the wounds were observed.
試料及び実験方法は次のとおりである。The samples and experimental methods are as follows.
（１）試料：表１ 表１（２）実験
方法
粉末試料の場合は創傷面全体をカバーするように散布し
、その上からガーゼを当て、包帯をした。軟膏の場合は
ガーゼにあらかじめ薄く塗付して、これを創傷面に貼付
した。(1) Sample: Table 1 Table 1 (2) Experimental method In the case of a powder sample, it was sprinkled to cover the entire wound surface, gauze was applied over it, and a bandage was applied. In the case of ointment, it was applied thinly to gauze in advance and applied to the wound surface.
各試料を創傷面に適用して１２時間後、ガーゼに対する
出血、血液の付着よごれの程度を止血効果の目安とし、
また、創傷の回復の状態を肉眼で観察した。評点は以下
のとおりとした。12 hours after applying each sample to the wound surface, the degree of bleeding and blood adhesion to the gauze is used as a guideline for the hemostatic effect.
In addition, the state of wound recovery was visually observed. The ratings were as follows.
（ガーゼに対する血液の付着、よごれの程度）はとんど
付着、よごれなし山−・−・・・・→−２やや付着、よ
ごれあり・・・・・・・−・・山・・・・・＋１付着、
よごれあり・・・・・・・・・・・・す・・・山・川・
０多
付着、よごれがやや陣い・・・・・・由・聞−１付着、
よごれが強い・・・・・・・・・・・−・・川・・・・
・−２（創傷の回復の状態）
創面又は創口の乾きが早く、力皮形成が早い ＋１（３
）結果と考察
表２に結果を示した。ボランティアによって症状がかな
り異なるので、投与の効果を同一条件で比較することは
難かしいが、はぼ同程度の受傷者について比較すると、
本発明品の投与を受けた場合の方が、出血の程度は軽く
、傷が早く乾き。(Blood adhesion to the gauze, extent of dirt) is mostly adhesion, no dirt - 2 Slight adhesion, dirt... - - mountain...・+1 attached,
Dirt...Mountains, rivers...
0 too much adhesion, a little bit of dirt...Y/N-1 adhesion,
Very dirty・・・・・・・・・・・・－・River...
・-2 (state of wound recovery) The wound surface or opening dries quickly, and force skin formation occurs quickly +1 (3
) Results and Discussion The results are shown in Table 2. Symptoms vary considerably between volunteers, so it is difficult to compare the effects of administration under the same conditions, but when comparing patients with similar injuries,
Those who received the inventive product experienced less bleeding and the wound dried more quickly.
力皮形成が促進されている。このことから１本発明製剤
はすぐれた止血及び創傷保護効果を発揮することがわか
る。Force skin formation is promoted. This shows that the formulation of the present invention exhibits excellent hemostasis and wound protection effects.
表２
〔実施例〕
実施例１
平均分子茄５４０万、平均粒子径１ｏμｍ、ナトリウム
置換度１００％のポリアクリル酸ナトリウムの粉末６０
部を１８０℃にて３時間加熱乾燥し、これに、十分乾燥
した馬れいしょ澱粉２０部、乳糖１９部、硫酸アラジオ
マイシフ１部を均一に混合した粉末１０ｉｉ’をポリエ
チレン製のびんに充てんする。Table 2 [Example] Example 1 Powder 60 of sodium polyacrylate with an average molecular weight of 5.4 million, an average particle diameter of 1 μm, and a degree of sodium substitution of 100%.
10ii' of powder was uniformly mixed with 20 parts of sufficiently dried horse starch, 19 parts of lactose, and 1 part of sulfuric acid aradiomycif, and filled in a polyethylene bottle. do.
実施例２
平均分子量１８０万、平均粒子径５μｍのナトリウム置
換度８０％ポリアクリル酸ナトリウムの粉末５０部、平
均粒子径１５μｍのゼラチンの粉末２０部、十分乾燥し
たトウモロコシ澱粉１０部。Example 2 50 parts of sodium polyacrylate powder with an average molecular weight of 1.8 million and an average particle size of 5 μm and a degree of sodium substitution of 80%, 20 parts of gelatin powder with an average particle size of 15 μm, and 10 parts of sufficiently dried corn starch.
フィブリノーゲン３部、乳糖１７部よりなる均一に混合
した粉末１０？をポリエチレン製のびんに充てんする。10 homogeneously mixed powder consisting of 3 parts fibrinogen and 17 parts lactose? Fill a polyethylene bottle.
実施例３ 平均分子量８１０万、平均粒子径４・１μｍ の。Example 3 Average molecular weight 8.1 million, average particle size 4.1 μm.
ナトリウム置換度＋００係の微粉末状のポリアクリル酸
ナトリウム粉末１０’ｉｌをポリエチレン製のびんに充
てんする。A polyethylene bottle is filled with 10 liters of finely powdered sodium polyacrylate powder with a degree of sodium substitution of +00.
特許出願人 日本化薬株式会社 一９完−Patent applicant: Nippon Kayaku Co., Ltd. 19 completed-
Claims (1)
末を含有する止血及び創傷保護剤Hemostatic and wound protection agent containing sodium polyacrylate powder with an average particle size of 140 μm or less
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21009485A JPS6270318A (en) | 1985-09-25 | 1985-09-25 | Hemostatic and wound-protecting agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21009485A JPS6270318A (en) | 1985-09-25 | 1985-09-25 | Hemostatic and wound-protecting agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6270318A true JPS6270318A (en) | 1987-03-31 |
Family
ID=16583716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21009485A Pending JPS6270318A (en) | 1985-09-25 | 1985-09-25 | Hemostatic and wound-protecting agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6270318A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083918A (en) * | 1991-07-31 | 2000-07-04 | Klaus; Edwin | Use of collagen for the treatment of degenerative articular processes |
| EP1408902A4 (en) * | 2001-06-22 | 2008-02-13 | Millard Marsden Mershon | Compositions and methods for reducing blood and fluid loss from open wounds |
| US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
| US9999703B2 (en) | 2012-06-12 | 2018-06-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
| CN108434510A (en) * | 2018-05-23 | 2018-08-24 | 宁波宝亭生物科技有限公司 | A kind of preparation method of modified starch hemostatic microsphere |
| US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
| US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
| US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
| US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
| US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
| US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
-
1985
- 1985-09-25 JP JP21009485A patent/JPS6270318A/en active Pending
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6165983A (en) * | 1991-07-31 | 2000-12-26 | Klaus; Edwin | Use of collagen for the treatment of degenerative articular processes |
| US6083918A (en) * | 1991-07-31 | 2000-07-04 | Klaus; Edwin | Use of collagen for the treatment of degenerative articular processes |
| EP1408902A4 (en) * | 2001-06-22 | 2008-02-13 | Millard Marsden Mershon | Compositions and methods for reducing blood and fluid loss from open wounds |
| US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
| US10799611B2 (en) | 2012-06-12 | 2020-10-13 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
| US9999703B2 (en) | 2012-06-12 | 2018-06-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
| US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
| US10595837B2 (en) | 2013-06-21 | 2020-03-24 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
| US11103616B2 (en) | 2013-12-11 | 2021-08-31 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
| US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
| US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
| US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
| US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
| US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
| US12544483B2 (en) | 2018-05-09 | 2026-02-10 | Ethicon Inc. | Method for preparing a haemostatic composition |
| CN108434510A (en) * | 2018-05-23 | 2018-08-24 | 宁波宝亭生物科技有限公司 | A kind of preparation method of modified starch hemostatic microsphere |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7291116B2 (en) | COMPOSITIONS FOR INTERFACE TYPE WOUND DRESSINGS | |
| US20200129654A1 (en) | Dressing Providing for the Controlled and Sustained Release of Metformin | |
| DE69816307T2 (en) | IN-SITU PRODUCTION OF POLYMER MATERIAL | |
| JP2735392B2 (en) | How to treat psoriasis | |
| US5314915A (en) | Bioadhesive pharmaceutical carrier | |
| RU2332238C2 (en) | Composition for pads, wound dressing and other articles contacting skin | |
| EP0927051B1 (en) | Novel hydrophile adhesive mass | |
| US4975426A (en) | Cough/cold mixtures comprising non-sedating antihistamine drugs | |
| JPH10152663A5 (en) | ||
| JPS6270318A (en) | Hemostatic and wound-protecting agent | |
| JPH06225932A (en) | Composition that is possible to extrude for local or percutanous medicine distribution | |
| US6313369B1 (en) | Structured occlusive dressing | |
| CA2081709A1 (en) | Controlled release pharmaceutical compositions | |
| MX2007001512A (en) | Adhesive composition. | |
| WO2000010537A1 (en) | Timed release tablet comprising naproxen and pseudoephedrine | |
| JP2001508038A (en) | Pharmaceutical gel preparations that can be applied to mucosal surfaces and body tissues | |
| JPH09328418A (en) | Compound for sustained release of medicine for medical used and its production | |
| JPH09208460A (en) | Patch | |
| WO1996009829A1 (en) | Improved topical carriers for mucosal applications | |
| JPS61271219A (en) | Nitro plaster | |
| JPS61155320A (en) | Plaster | |
| JPS61260014A (en) | Base for hydrous patch | |
| CN101361751B (en) | Hygroscopic self-adhesive anti-postoperative adhesion isolation film and preparation method thereof | |
| JPS62142112A (en) | Oral retention base | |
| BR9905261A (en) | A new programmed-release drug association |